Inspire Pharmaceuticals Inc., of Durham, N.C., said findings published in the American Journal of Respiratory and Critical Care Medicine showed that cystic fibrosis patients, age 5 and older, receiving inhaled denufosol had better lung exhalation rates than those in the placebo group at the end of 24 weeks in a Phase III trial.